Are ‘super donors’ the answer to sustainable growth for the allogeneic cell and gene therapy industry?

Why reliance on a small subset of donors could introduce risk for companies

Navigating a time-sensitive cell therapy supply chain during the coronavirus outbreak (Updated)

Why established systems and relationships matter

HLA matching could bring more allogeneic cell therapies to market, faster

An expert opinion on HLA matching relevance for allogeneic cell therapies

Advancements in Cell and Gene Therapy: 2019 Year-in-Review

Quality Starting Material: The Driving Force Behind Life-Saving Cell Therapies

By Jamie Margolis, PhD, Senior Vice President of Donor Services, NMDP/Be The Match

Cell collection standards for cell therapies

A case study from the Standards Coordinating Body developed in partnership with Be The Match BioTherapies

How to overcome 3 common cell therapy supply chain disruptions

Design a tailored logistics plan to deliver

Overcoming challenges to cellular starting material collection

Q&A with the Be The Match BioTherapies Collection Network Liaison team

Driving CAR-T therapy safety and sustainability for the road ahead

Q&A with Abby McDonald, PhD, Solutions Development Supervisor